Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious...
Faex Health Announces Investigational AI Screening Capabilities for Ebola and H. pylori, Expanding Gut Health Platform to 18 Conditions